FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C	20549
-----------------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average	burden								
hours per response	. 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CHANGES IN BENEFICIAL O
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of

l	d Address of	Reporting Person* $ \underline{M} $							er or Traceutics,		Symbol [ MRS	N ]		neck all ap	ctor	ng Pers	10% Ov	vner
(Last) (First) (Middle) C/O MERSANA THERAPEUTICS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 01/15/2021							belo	er (give title w)		Other (s below)	pecify	
840 MEMORIAL DRIVE					4. It	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	IDGE M	A	02139											X For	n filed by On n filed by Mo son		•	
(City)	(S	tate) (	Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
			2. Transaction Date (Month/Day/Year)			2A. Deemed Execution Date, if any (Month/Day/Year)		, Transaction Disposed Code (Instr. 5)		rities Acquired (A) ed Of (D) (Instr. 3, 4		Secur Benef	icially d Following	Form:	Direct Indirect Itstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) o (D)	r Price	Trans	action(s) 3 and 4)			msu. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	Execution Date, if any		4. Transaction Code (Instr. 8)		n of E		6. Date Exercisable a Expiration Date (Month/Day/Year)			and 7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)		8. Price of Derivativ Security (Instr. 5)		e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code V (A) (D)					Date Exercisab		xpiration ate	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$21.09	01/15/2021			A		4,528		(1)	0	1/15/2031	Common Stock	4,528	\$0	4,528	3	D	

## **Explanation of Responses:**

 $1. \ The \ option \ becomes \ exercisable \ in \ equal \ quarterly \ installments \ on \ the \ last \ day \ of \ each \ calendar \ quarter \ of \ 2021.$ 

/s/ Brian DeSchuytner, as Attorney-in-Fact

01/20/2021

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>\*</sup> If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).